Exam Passing Guarantee Jul 06, 2025 ACRP-CP Exam with Accurate Quastions!
Test Engine to Practice Test for ACRP-CP Valid and Updated Dumps
NEW QUESTION # 64
Who is responsible for submitting a protocol amendment to the IRB/IEC?
- A. Investigator
- B. Sponsor
- C. CRA
- D. CRC
Answer: A
Explanation:
The investigator holds the responsibility for submitting any protocol amendments to the IRB/IEC for review and approval. This step ensures that all changes are ethically evaluated before being implemented, maintaining compliance with regulatory requirements.
According to GCP guidelines, the investigator must submit protocol changes to the IRB/IEC to secure approval before making any modifications to the study.
"The investigator must inform the IRB/IEC of any proposed protocol changes and secure approval prior to implementation." Objectives:
* Maintain ethical oversight in study modifications.
* Adhere to regulatory submission requirements.
NEW QUESTION # 65
IP is dispensed to all subjects who:
- A. Screened for the trial.
- B. Need IP for their medical condition.
- C. Consented for the trial.
- D. Are eligible to receive it in the trial.
Answer: D
Explanation:
The investigational product (IP) is only dispensed to subjects who meet the eligibility criteria as defined in the study protocol. Eligibility is confirmed during screening and baseline assessments. Simply consenting to the trial does not guarantee receipt of IP.
According to GCP guidelines, IP dispensing must strictly follow eligibility criteria to maintain protocol compliance and subject safety.
"IP should only be dispensed to subjects who have been deemed eligible according to the protocol's inclusion and exclusion criteria." Objectives:
* Maintain adherence to protocol criteria.
* Protect participant safety by ensuring proper eligibility.
NEW QUESTION # 66
A PI is being considered for an industry-sponsored study. The PI sees approximately 20 patients per month who meet the study criteria. The PI does not have access to a Positron Emission Tomography (PET) scanner, which is required for the protocol. The PI is already taking part in three other studies. Should the Sponsor choose this PI?
- A. Yes, the PI has a sufficient patient population to take part in this study.
- B. Yes, the PI can perform other imaging scans instead of the PET scans.
- C. No, the PI does not have the resources to perform all protocol-required procedures.
- D. No, the PI is taking part in too many ongoing studies to participate in this study.
Answer: C
Explanation:
The PI lacks access to a PET scanner, a required element for conducting the study according to the protocol.
Without this essential equipment, the PI cannot fully meet the study requirements, making it unsuitable for the sponsor to select this site. Compliance with the protocol's technical requirements is crucial for the trial's success.
GCP guidelines state that investigators must have access to all necessary facilities and equipment to conduct the trial as outlined in the protocol.
"The investigator must have adequate resources, including access to required equipment, to perform the study as specified." Objectives:
Ensure site readiness for protocol requirements.
Prevent protocol deviations due to inadequate resources.
NEW QUESTION # 67
A sponsor wants to transfer duties to a CRO. Which of the following statements is the MOST correct?
- A. Any trial-related duties can be documented as transferred by verbal agreement.
- B. Regulatory authorities must be notified promptly of the transfer of any duties to a CRO.
- C. All duties transferred to a CRO should be specified in writing.
- D. The IRB/IEC must approve the transfer of duties to a CRO.
Answer: C
Explanation:
When a sponsor transfers specific tasks to a Contract Research Organization (CRO), it must be documented in writing. This formal documentation clearly delineates responsibilities and ensures that both parties are aware of their roles and obligations. Verbal agreements are not sufficient forregulatory compliance.
ICH E6(R2) GCP guidelines mandate that all delegated tasks must be documented formally to ensure clarity and compliance.
"The sponsor should document in writing any responsibilities transferred to a CRO to ensure clear delineation of roles." Objectives:
* Maintain clear documentation of delegated tasks.
* Ensure compliance with regulatory standards.
NEW QUESTION # 68
A study has been closed for two years after the last approval of a marketing application of an IP. No additional applications are pending and there are no further developments planned for the IP. Which of the following statements is the BEST course of action regarding the destruction of the essential documents?
- A. The site should contact the sponsor and receive verbal notification they are no longer needed andthe essential documents may be destroyed.
- B. The site may proceed with the destruction of the essential documents.
- C. The site should retain the essential documents longer to meet the regulatory requirements.
- D. The site should contact the sponsor and receive written notification prior to destruction that the essential documents are no longer needed.
Answer: D
Explanation:
Before destroying any essential documents, the site must obtain written confirmation from the sponsor that these documents are no longer needed. This ensures compliance with regulatory requirements, as some countries may require document retention for longer periods, even after study closure and marketing approval.
GCP guidelines state that the sponsor must confirm in writing that essential documents can be destroyed after ensuring compliance with local regulations.
"Before destroying essential documents, written confirmation from the sponsor is required to ensure compliance with regulatory retention policies." Objectives:
* Maintain compliance with document retention regulations.
* Prevent premature destruction of essential trial records.
NEW QUESTION # 69
While reviewing reports of data completion, the sponsor notices low retention rates at many participating sites. What is an appropriate FIRST action for the sponsor to take?
- A. Submit revised ICFs to the IRB/IEC with increased compensation for participants.
- B. Meet with the site staff to understand their workflows and to review retention strategies.
- C. Require participants to provide documented reason for withdrawal.
- D. Interview participants who have dropped out.
Answer: B
Explanation:
Meeting with site staff to understand workflows and retention strategies is the most practical first step. By engaging with the team, the sponsor can identify potential issues affecting retention, such as site-related factors, participant burden, or protocol complexities. Addressing these issues collaboratively can improve retention without needing major protocol changes.
GCP guidelines recommend assessing and understanding site-specific challenges before making procedural changes or protocol amendments.
"Engaging with site staff to discuss retention issues helps identify root causes and develop practical solutions." Objectives:
* Improve participant retention through collaboration.
* Identify and address site-specific challenges.
NEW QUESTION # 70
Which of the following reports should be retained in participant charts?
- A. IRB/IEC progress reports
- B. Safety reports
- C. DSMB/IDMC reports
- D. Lab reports
Answer: D
Explanation:
Lab reports contain individual participant data relevant to their health status and the study's outcomes. These reports are essential for verifying subject safety and evaluating the effects of the investigational product (IP).
Therefore, they must be retained in the participant's medical records.
According to GCP guidelines, participant charts must include laboratory data as part of the essential documents to ensure accurate and complete clinical records.
"Lab reports must be maintained as part of the participant's chart for safety monitoring and data verification." Objectives:
* Maintain comprehensive medical records for each participant.
* Ensure availability of clinical data for audit and review.
NEW QUESTION # 71
Who takes responsibility for initiating a clinical trial?
- A. Investigator
- B. Sponsor
- C. IRB/IEC
- D. CRO
Answer: B
Explanation:
The sponsor is responsible for initiating a clinical trial. This involves developing the protocol, securing funding, selecting study sites, and obtaining regulatory approvals. The sponsor also oversees the conduct of the trial to ensure compliance with GCP and regulatory requirements.
According to GCP guidelines, the sponsor is the entity that initiates, manages, and finances the clinical investigation.
"The sponsor is responsible for initiating, managing, and financing the clinical trial, including protocol development and site selection." Objectives:
* Understand the sponsor's role in trial initiation.
* Ensure compliance from the outset of the study.
NEW QUESTION # 72
Which statement does NOT represent a study monitor's responsibilities?
- A. Report serious adverse events to the IRB/IEC.
- B. Verify that the PI has adequate qualifications and resources to conduct the study.
- C. Check the accuracy and completeness of case report forms with source documents.
- D. Provide communication between the sponsor and the PI.
Answer: A
Explanation:
It is not the monitor's responsibility to report serious adverse events (SAEs) to the IRB/IEC. This responsibility typically falls on the PI or the sponsor. Monitors focus on data accuracy, protocol compliance, and communication between the site and the sponsor.
The answer follows GCP standards where the monitor's role is clearly defined, excluding SAE reporting to IRB/IEC.
"Monitors are responsible for verifying data accuracy and communicating with the sponsor but not for direct reporting of SAEs to the IRB/IEC." Objectives:
* Distinguish between the responsibilities of monitors and investigators
* Clarify SAE reporting protocols
NEW QUESTION # 73
A new device trial is being considered. Before committing to participate in the trial, what is the MOST important item the PI needs to evaluate?
- A. Location of stored trial records
- B. Length of time to receive the approved trial device
- C. Availability of qualified staff to conduct the trial
- D. Information to be included in the advertising flyer
Answer: C
Explanation:
The availability of qualified staff to conduct the trial is essential for maintaining compliance with protocol requirements and ensuring patient safety. Without adequately trained and available staff, the trial's integrity and data quality are compromised.
This answer is based on GCP guidelines emphasizing the importance of having trained and qualified personnel before initiating a trial.
"The PI must ensure that sufficient qualified staff is available to conduct the trial as per the protocol and regulatory requirements." Objectives:
* Assessing resource availability
* Ensuring readiness to initiate a clinical trial
NEW QUESTION # 74
A potential subject is interested in a new clinical trial and would like to learn more about the risks and benefits of participation. Where can they find this information?
- A. IB
- B. Protocol
- C. ICF
- D. Package insert
Answer: C
Explanation:
The Informed Consent Form (ICF) contains comprehensive information about the potential risks and benefits of participation in a clinical trial. It is a legally required document that ensures that subjects make an informed decision before enrollment.
The answer is consistent with GCP guidelines which mandate that the ICF clearly outlines the risks and benefits of participation to protect participant rights.
"The ICF should include a clear explanation of potential risks and benefits to ensure informed decision- making by the participant." Objectives:
* Ensure informed decision-making by potential subjects.
* Provide transparent risk-benefit information.
NEW QUESTION # 75
Which strategy is used to safeguard subject privacy?
- A. Store source documentation in the CRC's office.
- B. Email updated enrollment logs to the CRA.
- C. Utilize subject initials on correspondence.
- D. Conduct subject-related conversations in controlled environments.
Answer: D
Explanation:
Conducting subject-related conversations in controlled environments ensures that personal and sensitive information is not overheard or disclosed to unauthorized individuals. This practice upholds patient confidentiality as required by GCP and data protection regulations.
The answer follows GCP guidelines for protecting the privacy and confidentiality of clinical trial participants.
"Conversations regarding study subjects should be held in secure and controlled environments to protect personal data." Objectives:
* Ensuring confidentiality in clinical trial settings.
* Protecting patient privacy according to ethical standards.
NEW QUESTION # 76
While consenting a potential subject, a coordinator discovered the subject could not read. Under what conditions can this potential subject be enrolled?
- A. Locate a translator and have them work with the person.
- B. Have the Principal Investigator consent the person.
- C. There are no circumstances under which this person can be enrolled.
- D. Get an impartial witness involved in consenting this person.
Answer: D
Explanation:
When a participant cannot read, an impartial witness must be present during the consent process. The witness ensures that the information is accurately presented and that the subject's consent is truly informed. The witness must sign the consent form to attest that the subject understands the information.
GCP guidelines require the use of an impartial witness during the informed consent process for individuals who are illiterate or visually impaired.
"Informed consent must involve an impartial witness when the subject cannot read, ensuring the consent process is conducted ethically." Objectives:
* Maintain ethical standards during consent.
* Protect the rights of participants with literacy challenges.
NEW QUESTION # 77
AEs that occur between study visits of a clinical trial should be evaluated by the:
- A. Medical monitor
- B. Principal Investigator
- C. Subject's primary care physician
- D. Study pharmacovigilance physician
Answer: B
Explanation:
The Principal Investigator (PI) is responsible for evaluating Adverse Events (AEs) that occur between study visits. The PI must assess the severity, causality, and potential relationship to the investigational product (IP).
Proper evaluation ensures that any necessary medical interventions are promptly administered and that relevant information is recorded and reported accurately.
GCP guidelines specify that the PI is accountable for the medical care of trial subjects, including evaluating AEs and ensuring their safety.
"The PI must evaluate any adverse events occurring between study visits to determine their relevance to the investigational product and manage patient care." Objectives:
* Ensure prompt and accurate evaluation of AEs.
* Maintain the safety and well-being of study participants.
NEW QUESTION # 78
Which document confirms the PI's agreement to permit auditing at the study site?
- A. Delegation Log
- B. IB
- C. Protocol
- D. ICF
Answer: D
Explanation:
The Informed Consent Form (ICF) typically includes a statement indicating that the participant's records may be reviewed by monitors, auditors, and regulatory authorities. This ensures transparency and compliance with regulatory requirements, allowing for audits and inspections when necessary.
This answer follows GCP guidelines which specify that the ICF should include consent for audits and inspections to protect subject confidentiality while ensuring data integrity.
"The ICF must include a statement allowing access to trial data for monitoring, auditing, and regulatory inspection purposes." Objectives:
* Ensure informed consent for data access.
* Facilitate compliance with auditing requirements.
NEW QUESTION # 79
A site is starting up a Phase III trial. They have received IRB/IEC approval and have scheduled the SIV. The site cannot begin enrolling subjects until:
- A. A signed clinical trial agreement between the site and sponsor is in place.
- B. The CRA has performed source document review and verification at the site.
- C. The DSMB meets and the first DSMB meeting report has been issued.
- D. The site receives approval from the medical monitor to begin enrolling.
Answer: A
Explanation:
Before a clinical trial site can begin enrolling participants, there must be a signed clinical trial agreement (CTA) between the site and the sponsor. This agreement outlines the responsibilities, financial arrangements, and expectations between both parties, ensuring that the trial is conducted in compliance with regulatory and ethical standards.
GCP guidelines require that a formal agreement be in place before trial initiation to protect the rights and obligations of both the sponsor and the site.
"Before subject enrollment can commence, the sponsor and site must finalize a clinical trial agreement, establishing legal and ethical commitments." Objectives:
* Ensure proper contractual arrangements before trial initiation.
* Protect legal rights and obligations of involved parties.
NEW QUESTION # 80
At a close-out visit, which document should be retained only at the site?
- A. Final trial close-out monitoring report
- B. Subject identification code list
- C. IP accountability
- D. Treatment allocation
Answer: B
Explanation:
The subject identification code list, which links the participant's unique code to their personal information, must be retained only at the site. This list ensures confidentiality and is necessary for identifying participants during follow-up. It is not shared with the sponsor to protect participant privacy.
GCP guidelines mandate that the subject identification code list remains at the site to ensure confidentiality and compliance with data protection regulations.
"The subject identification code list must be securely stored at the site to maintain participant confidentiality." Objectives:
* Safeguard participant confidentiality.
* Maintain compliance with data protection policies.
NEW QUESTION # 81
......
Exam Questions for ACRP-CP Updated Versions With Test Engine: https://freepdf.passtorrent.com/ACRP-CP-latest-torrent.html